Key Takeaways
- Johnson & Johnson received FDA clearance for Icotyde, an oral plaque psoriasis medication created alongside Protagonist Therapeutics (PTGX), pushing ABBV down approximately 4.69%
- The newly approved once-daily oral medication poses a direct challenge to AbbVie’s leading immunology product, Skyrizi
- Wall Street forecasts indicate Skyrizi sales could still climb 23% through FY2026 despite intensifying competition
- ABBV is currently positioned beneath critical moving averages: SMA-20 ($227.73), SMA-50 ($224.27), and narrowly below SMA-200 ($214.95), signaling bearish momentum
- The pharmaceutical giant outlined FY2026 earnings per share expectations between $14.37 and $14.57, while also revealing a strategic collaboration with Alloy Therapeutics for antibody development
Shares of AbbVie (ABBV) tumbled approximately 4.69% during Tuesday’s session following regulatory approval granted by the FDA to Johnson & Johnson’s (JNJ) innovative plaque psoriasis medication, Icotyde. The market reaction underscored investor concerns about potential revenue headwinds for Skyrizi, a cornerstone of AbbVie’s strategy to offset declining Humira sales.
Created through a partnership between J&J and Protagonist Therapeutics (PTGX), Icotyde represents a once-daily oral alternative for treating plaque psoriasis. This positions the medication as a head-to-head competitor against Skyrizi, which serves as one of AbbVie’s most critical immunology franchise assets.
However, Wall Street remains cautiously optimistic about Skyrizi’s prospects. The medication’s clinical performance profile and administration schedule continue to be viewed as competitive differentiators, with forecasts suggesting revenue growth of 23% through fiscal year 2026.
Shares settled near $212.50 following an opening below the previous day’s closing price of $218.60. Intraday trading spanned from $209.42 to $218.60, demonstrating significant bearish pressure throughout the session.
Chart Analysis Indicates Downward Pressure
From a technical perspective, ABBV is trading beneath its SMA-20 ($227.73), SMA-50 ($224.27), and marginally below its SMA-200 ($214.95). This configuration across major moving averages presents a decidedly bearish technical setup.
Relative Strength Index readings on both daily and weekly timeframes have entered sell zones. The Commodity Channel Index and Bollinger Band Position indicators reflect oversold conditions alongside negative price momentum. The Average Directional Index remains subdued, indicating the absence of a definitive trend, while MACD readings show neutral positioning.
Immediate support appears at $210.83. A decisive breach below this threshold could trigger additional selling pressure. Upside resistance is identified at the Ichimoku Kijun level of $227.58.
Traders are monitoring a potential range-bound pattern between $210.83 and $215.22, with some market participants anticipating a bounce should prices consolidate near the lower boundary.
The 200-day simple moving average at $214.95 could provide temporary support, though the preponderance of technical indicators suggests continued downside risk.
Post-Humira Challenges and Aesthetics Weakness
The competitive dynamics introduced by Icotyde emerge during a challenging period for AbbVie. The pharmaceutical company continues navigating revenue headwinds from Humira’s patent expiration, while its aesthetics division — featuring products like Juvederm — experiences ongoing sales deterioration.
Recent portfolio adjustments by institutional investors show reductions in ABBV holdings, reflecting evolving market sentiment toward the shares. Corporate insider transactions have been one-sided, with two disposal transactions recorded over the previous three months and zero acquisitions.
On a more constructive note, AbbVie unveiled a multi-year strategic collaboration with Alloy Therapeutics focused on creating a next-generation antibody discovery platform. The arrangement includes initial payments and performance-based financial commitments, demonstrating sustained investment in research and development initiatives.
Management also provided fiscal 2026 earnings per share guidance ranging from $14.37 to $14.57, signaling confidence in the organization’s fundamental business trajectory despite competitive headwinds.
Wall Street’s consensus price target stands at $251.44, accompanied by a 2.2 recommendation score — indicating a moderate buy rating. Institutional ownership remains substantial at 74.71% of outstanding shares.
According to GF Value metrics, ABBV holds an estimated value of $198.80, with current trading levels considered fairly valued relative to fundamentals.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
